MIMasayuki Imamura

Masayuki Imamura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masayuki Imamura has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors

    by Hirofumi Watanabe, Fumiyoshi Fujishima, Izumi Komoto, Masayuki Imamura, Susumu Hijioka, Kazuo Hara, Yasushi Yatabe, Atsushi Kudo, Toshihiko Masui, Takahiro Tsuchikawa, et al.

    Somatostatin analogues (SSAs) are widely used to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Somatostatin receptor 2 (SSTR2) immunoreactivity serves as a predictive marker of the therapeutic efficacy of SSAs in pancreatic NETs. However, SSTR2 expression profiles in tumor cells and their association with the therapeutic efficacy of SSAs remains virtually unknown in gastrointestinal NETs (GI-NETs). Therefore, we evaluated the association between SSTR2 immunoreactivity and embryological origin and proliferative activity in 132 resected surgical tissues of GI-NETs. The correlation between SSAs’ therapeutic efficacy and SSTR2 immunoreactivity was evaluated in 14 GI-NETs treated with SSAs. SSTR2 immunoreactivity was evaluated using Volante scores, immunoreactive scores, and digital image analysis (DIA). SSTR2 immunoreactivity was significantly negatively and positively correlated with the Ki-67 labeling index in foregut and hindgut NETs, respectively. In the normal mucosa, neuroendocrine cells in the rectum had significantly lower positive rates of SSTR2 than those in the stomach and duodenum. SSTR2 expression profiles in GI-NETs could differ by primary sites, while the difference of those between foregut and hindgut NETs might be derived from the SSTR2 status of normal neuroendocrine cell counterparts. In addition, DIA could provide a good alternative for predicting response to SSAs in evaluating SSTR2 immunoreactivity of GI-NETs.


  • The factors associated with the malignant nature in Japanese patients with pNETs: Data from a nationwide survey

    by Hisato Igarashi, Tetsuhide Ito, Atsuko Kasajima, Takuji Okusaka, Koji Takano, Izumi Komoto, Ryuichiro Doi, Hironobu Sasano, Masayuki Imamura, Akira Shimatsu

    • 1 November 2015
      • Vol. 42  (12) , 1692-4

    [Adult Case of Invagination Due to Small Intestinal Metastases of Malignant Melanoma].

    by Atsushi Ikeda, Akifumi Kanazawa, Yoshiyuki Miura, Yohei Hosoda, Hidekazu Esaki, Naoya Inoue, Masaaki Awane, Shoji Tsunekawa, Yoshiro Taki, Masayuki Imamura

    An 84-year-old woman was diagnosed with malignant melanoma after resection of a nasal cavity tumor in February 2008. In April 2010, she underwent small bowel resection because of ileus due to small intestinal metastases. She was diagnosed with ileus again in October 2010. Computed tomography (CT) and 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) revealed invagination of the small intestine and small intestinal metastases. We performed a palliative small bowel resection. She had a good postoperative course and was discharged 2 weeks after surgery. Oral intake was possible for 6 months until her death.

  • Open Access

    A case of insulinoma with non-alcoholic fatty liver disease: Roles of hyperphagia and hyperinsulinemia in pathogenesis of the disease

    by Mariyo Rokutan, Daisuke Yabe, Izumi Komoto, Takeshi Kurose, Jun Kawai, Takefumi Nakamura, Masayuki Imamura, Yutaka Seino

    Nonalcoholic fatty liver disease (NAFLD) is a serious health-related condition all over the world; the number of patients is increasing in Asian countries including Japan. Better understanding of its pathophysiology is required to develop effective therapeutics, as patients may go on to develop non-alcoholic steatohepatitis and hepatocellular carcinomas. While NAFLD is believed to be associated with metabolic risk factors such as obesity, diabetes, and dyslipidemia, its etiology remains largely unknown and the development or co-existence of NAFLD in patients with insulinoma has not been investigated. A 33-year-old male with an insulinoma, who had been hypoglycemic during the previous four years, developed abnormally elevated levels of liver enzymes and histological fatty liver characteristic of NAFLD by the time of admission to our hospital for resection of an insulinoma. His medical records for the previous eight years revealed that his bodyweight had increased gradually from 60 kg to 71 kg for seven years and then acutely increased to 79 kg in the latest one-year period. This sudden increase was thought to be due to the patient's self-described overeating of fruits to forestall hypoglycemia. Fresh fruits are rich in fructose, and the patient's triglycerides, alanine and aspartate transaminases showed an acute increase in the previous one-year period. After resection of the insulinoma, the levels of these parameters all were mostly restored, which suggests that hyperinsulinemia and subsequent hyperphagia played a role in the development of NAFLD in this case. This is the first report of patient with NAFLD and an insulinoma.


    • 1 December 2014
      • Vol. 111  (12) , 2263-71

    Diagnosis for the gastroenteropancreatic neuroendocrine tumors.

    by Izumi Komoto, Masayuki Imamura


    • 1 November 2012
      • p. 492-5

    [Molecular target therapy for gastroenteropancreatic neuroendocrine tumors].

    by Naoya Inoue, Izumi Komoto, Masaaki Awane, Masayuki Imamura

  • Open Access

    Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients

    by Masayuki Imamura

    To search for the optimal surgery for gastrinoma and duodenopancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1. Sixteen patients with genetically confirmed multiple endocrine neoplasia type 1 (MEN 1) and Zollinger-Ellison syndrome (ZES) underwent resection of both gastrinomas and duodenopancreatic neuroendocrine tumors (NETs) between 1991 and 2009. For localization of gastrinoma, selective arterial secretagogue injection test (SASI test) with secretin or calcium solution was performed as well as somatostatin receptor scintigraphy (SRS) and other imaging methods such as computed tomography (CT) or magnetic resonance imaging (MRI). The modus of surgery for gastrinoma has been changed over time, searching for the optimal surgery: pancreaticoduodenectomy (PD) was first performed guided by localization with the SAST test, then local resection of duodenal gastrinomas with dissection of regional lymph nodes (LR), and recently pancreas-preserving total duodenectomy (PPTD) has been performed for multiple duodenal gastrinomas. Among various types of preoperative localizing methods for gastrinoma, the SASI test was the most useful method. Imaging methods such as SRS or CT made it essentially impossible to differentiate functioning gastrinoma among various kinds of NETs. However, recent imaging methods including SRS or CT were useful for detecting both distant metastases and ectopic NETs; therefore they are indispensable for staging of NETs. Biochemical cure of gastrinoma was achieved in 14 of 16 patients (87.5%); that is, 100% in 3 patients who underwent PD, 100% in 6 patients who underwent LR (although in 2 patients (33.3%) second LR was performed for recurrence of duodenal gastrinoma), and 71.4% in 7 patients who underwent PPTD. Pancreatic NETs more than 1 cm in diameter were resected either by distal pancreatectomy or enucleations, and no hepatic metastases have developed postoperatively. Pathological study of the resected specimens revealed co-existence of pancreatic gastrinoma with duodenal gastrinoma in 2 of 16 patients (13%), and G cell hyperplasia and/or microgastrinoma in the duodenal Brunner's gland was revealed in all of 7 duodenal specimens after PPTD. Aggressive resection surgery based on accurate localization with the SASI test was useful for biochemical cure of gastrinoma in patients with MEN 1.


  • Open Access

    Recent standardization of treatment strategy for pancreatic neuroendocrine tumors

    by Masayuki Imamura

    Recent standardization of treatment strategy for pancreatic neuroendocrine tumors


    • 11 April 2007
      • Vol. 54  (73) , 36-40

    Clinicopathological significance of aminopeptidase N/CD13 expression in human gastric carcinoma.

    by Junichiro Kawamura, Yutaka Shimada, Hidenori Kitaichi, Izumi Komoto, Yosuhe Hashimoto, Junichi Kaganoi, Masayuki Miyake, Seiji Yamasaki, Kan Kondo, Masayuki Imamura

    Aminopeptidase N (APN)/CD13 is a transmembrane ectoenzyme occurring in a wide variety of cells. Recently, APN/CD13 has been reported to be involved in tumor invasion and metastasis. However, precise functions in tumor cells, and its role in gastric carcinoma remain unclear. To evaluate the role of APN/CD13 in gastric carcinoma, we conducted immunohistochemical staining for APN/CD13 in 121 gastric carcinoma specimens, using anti-APN monoclonal antibody. The relationship between APN/CD13 expression and various prognostic factors of gastric carcinoma were investigated. Of the 121 patients with gastric carcinoma studied, 48 were strongly positive, 36 were weakly positive, and 37 were negative. Overall survival rate of the patients with negative APN/CD13 expression was significantly lower than that of the patients with positive APN/CD13 expression. APN/CD13 expression was negatively associated with lymph node metastasis. Multivariate analysis showed APN/CD13 expression to be a significant prognostic factor. Decreased expression of APN/CD13 was associated with a poor prognosis. Hence, our results demonstrate that the immunohistochemical detection of APN/CD13 could provide useful information as one of the prognostic factors in gastric cancer.


    • 1 April 2004
      • Vol. 101  (4) , 367-72

    [Diagnosis and treatment for gastrinoma].

    by Masayuki Imamura, Izumi Komoto, Ryuichiro Doi, Yutaka Shimada